| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c38df77cfc0b02dcfc683a845e15484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71872d6f40adfb45b8a8731e75e2f43f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eec8878ed3b4fa03b284adc358831137 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 |
| filingDate |
2007-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01ae73f7b975436b8345cd68b7cae543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76a7fcf190af234425e4fe3b4a7ecf49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d7ffcbbb8264ebacadaa8f2d2651158 |
| publicationDate |
2011-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011039908-A1 |
| titleOfInvention |
Inhibiting Amyloid-Beta Peptide/Rage Interaction At The Blood-Brain Barrier |
| abstract |
Small molecules are used to inhibit specific receptor-ligand interaction between Alzheimer's amyloid-β peptide (Aβ) and Receptor for Advanced Gly-cation Endproducts (RAGE). Objectives include treating Alzheimer's disease and other pathologies involving cerebral amyloid angiopathy; improving blood flow to or within the brain; decreasing the level of Aβ in the brain; reducing neuropathology associated with Alzheimer's disease; reducing inflammation and/or oxidant stress in the brain; improving memory and/or learning; treating other conditions involving Aβ/RAGE interaction at the blood-brain barrier, RAGE-mediated transport of Aβ into the brain, or RAGE activation in brain vasculature and/or brain parenchyma (e.g., diabetic complications); or any combination thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104628822-A |
| priorityDate |
2006-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |